Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Nizar M. Tannir, MD, on Nivolumab Plus Ipilimumab vs Sunitinib: Choosing Therapy and Managing Toxicities

Posted: Wednesday, February 19, 2020

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses, in light of long-term findings, the combination therapy nivolumab plus ipilimumab, and whether sunitinib is still the best first-line option for patients with favorable-risk disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.